Barclays’s Puma Biotechnology PBYI Stock Holding History

Barclays’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,500	Closed	-$13K	–	6383
2019 Q4	$13K	Hold	1,500	–	–	﹤0.01%	6062
2019 Q3	$16K	Buy	+1,500	New	+$16.2K	﹤0.01%	6260
2019 Q1	–	Sell	-1,200	Closed	-$24K	–	7241
2018 Q4	$24K	Sell	1,200 -1,600	-57%	-$48K	﹤0.01%	5817
2018 Q3	$128K	Sell	2,800 -57,200	-95%	-$2.76M	﹤0.01%	5352
2018 Q2	$3.55M	Buy	60,000 +58,900	+5,355%	+$3.41M	﹤0.01%	2029
2018 Q1	$75K	Sell	1,100 -25,100	-96%	-$1.88M	﹤0.01%	5595
2017 Q4	$2.59M	Buy	26,200 +26,000	+13,000%	+$2.91M	﹤0.01%	2206
2017 Q3	$24K	Sell	200 -5,200	-96%	-$484K	﹤0.01%	5725
2017 Q2	$472K	Buy	5,400 +5,200	+2,600%	+$291K	﹤0.01%	3586
2017 Q1	$7K	Sell	200 -3,700	-95%	-$135K	﹤0.01%	6192
2016 Q4	$120K	Buy	+3,900	New	+$169K	﹤0.01%	4624
2015 Q3	–	Sell	-90,000	Closed	-$10.4M	–	6984
2015 Q2	$10.4M	Buy	+90,000	New	+$16.3M	0.01%	1005
2014 Q3	–	Sell	-77,900	Closed	-$5.14M	–	7774
2014 Q2	$5.14M	Buy	+77,900	New	+$5.54M	0.01%	1716
2013 Q4	–	Sell	-5,800	Closed	-$307K	–	7639
2013 Q3	$307K	Buy	+5,800	New	+$313K	﹤0.01%	4610

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's PBYI Position: Q2 2026 in Review

Barclays reduced its Puma Biotechnology (PBYI) stake by 20% in Q2 2026, selling an estimated $20.4K and leaving 11,202 shares worth $90.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4082.

Barclays first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.5M in Q3 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Barclays held 11,202 shares of Puma Biotechnology worth $90.8K as of Q2 2026.
Barclays sold 2,786 Puma Biotechnology shares in Q2 2026, an estimated $20.4K.
Puma Biotechnology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4082 holding.
Barclays first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
Barclays's Puma Biotechnology position peaked at $22.5M in Q3 2017.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.